Vaccine Vectors Harnessing the Power of Cytomegaloviruses
- PMID: 31627457
- PMCID: PMC6963789
- DOI: 10.3390/vaccines7040152
Vaccine Vectors Harnessing the Power of Cytomegaloviruses
Abstract
Cytomegalovirus (CMV) species have been gaining attention as experimental vaccine vectors inducing cellular immune responses of unparalleled strength and protection. This review outline the strengths and the restrictions of CMV-based vectors, in light of the known aspects of CMV infection, pathogenicity and immunity. We discuss aspects to be considered when optimizing CMV based vaccines, including the innate immune response, the adaptive humoral immunity and the T-cell responses. We also discuss the antigenic epitopes presented by unconventional major histocompatibility complex (MHC) molecules in some CMV delivery systems and considerations about routes for delivery for the induction of systemic or mucosal immune responses. With the first clinical trials initiating, CMV-based vaccine vectors are entering a mature phase of development. This impetus needs to be maintained by scientific advances that feed the progress of this technological platform.
Keywords: cytomegalovirus; immunization; immunotherapy; memory inflation; vaccine development; vaccine vector.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection.J Immunother Cancer. 2019 Jan 31;7(1):25. doi: 10.1186/s40425-019-0500-9. J Immunother Cancer. 2019. PMID: 30704520 Free PMC article.
-
Vaccine vectors: the bright side of cytomegalovirus.Med Microbiol Immunol. 2019 Aug;208(3-4):349-363. doi: 10.1007/s00430-019-00597-7. Epub 2019 Mar 21. Med Microbiol Immunol. 2019. PMID: 30900089 Review.
-
Revisiting CD8 T-cell 'Memory Inflation': New Insights with Implications for Cytomegaloviruses as Vaccine Vectors.Vaccines (Basel). 2020 Jul 22;8(3):402. doi: 10.3390/vaccines8030402. Vaccines (Basel). 2020. PMID: 32707744 Free PMC article.
-
Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.Immunotherapy. 2016 Feb;8(2):211-21. doi: 10.2217/imt.15.110. Epub 2016 Jan 20. Immunotherapy. 2016. PMID: 26786895 Free PMC article. Review.
-
Delineating the role of CD4+ T cells in the activation of human cytomegalovirus-specific immune responses following immunization with Ad-gBCMVpoly vaccine: implications for vaccination of immunocompromised individuals.J Gen Virol. 2010 Dec;91(Pt 12):2994-3001. doi: 10.1099/vir.0.025742-0. Epub 2010 Sep 1. J Gen Virol. 2010. PMID: 20810748
Cited by
-
Exploring the Potential of Cytomegalovirus-Based Vectors: A Review.Viruses. 2023 Oct 2;15(10):2043. doi: 10.3390/v15102043. Viruses. 2023. PMID: 37896820 Free PMC article. Review.
-
Construction and Characterization of a High-Capacity Replication-Competent Murine Cytomegalovirus Vector for Gene Delivery.Vaccines (Basel). 2024 Jul 18;12(7):791. doi: 10.3390/vaccines12070791. Vaccines (Basel). 2024. PMID: 39066429 Free PMC article.
-
Epidemiology and biology of a herpesvirus in rabies endemic vampire bat populations.Nat Commun. 2020 Nov 23;11(1):5951. doi: 10.1038/s41467-020-19832-4. Nat Commun. 2020. PMID: 33230120 Free PMC article.
-
Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection.Vaccines (Basel). 2020 Sep 14;8(3):526. doi: 10.3390/vaccines8030526. Vaccines (Basel). 2020. PMID: 32937764 Free PMC article.
-
Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice.Microbiol Spectr. 2023 Dec 12;11(6):e0246323. doi: 10.1128/spectrum.02463-23. Epub 2023 Nov 16. Microbiol Spectr. 2023. PMID: 37971259 Free PMC article.
References
-
- Boppana S.B., Britt W.J. Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Volume 2. Caister Academic Press; Poole, UK: 2013. Synopsis of clinical aspects of human cytomegalovirus disease; pp. 1–25.
-
- Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005;202:673–685. doi: 10.1084/jem.20050882. - DOI - PMC - PubMed
-
- Brune W. Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Volume 1. Caister Academic Press; Poole, UK: 2013. Molecular basis of cytomegalovirus host species specificity; pp. 322–329.
-
- Seckert C.K., Grießl M., Büttner J.K., Scheller S., Simon C.O., Kropp K.A., Renzaho A., Kühnapfel B., Grzimek N.K., Reddehase M.J. Viral latency drives ‘memory inflation’: A unifying hypothesis linking two hallmarks of cytomegalovirus infection. Med. Microbiol. Immunol. 2012;201:551–566. doi: 10.1007/s00430-012-0273-y. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials